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Context: Magnetic resonance imaging (MRI), with or without MRI-targeted biopsy (MRI
pathway), is an alternative test to systematic transrectal ultrasonography-guided biopsy
in men suspected of having prostate cancer. At present, evidence on which test to use is
insufficient to inform detailed evidence-based decision making.
Objective: To determine the diagnostic accuracy of the index tests MRI only, MRI-
targeted biopsy, MRI pathway, and systematic biopsy, as compared with template-
guided biopsy (reference standard), in detecting clinically significant prostate cancer,
defined as International Society of Urological Pathology grade 2 or higher, in biopsy-
naive men or those with a prior-negative biopsy (or mix of both).
Evidence acquisition: We systematically searched the literature and considered for
inclusion any cross-sectional study if it investigated (1) one or more index tests verified
by the reference standard, and (2) paired testing of the MRI pathway with systematic
biopsy. Quality and certainty of evidence were assessed by the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) and Grading of Recommendations Assessment,
Development and Evaluation, respectively.
Evidence synthesis: Accuracy analyses: Using a baseline cancer prevalence of 30%, MRI
pathway (sensitivity 0.72 [95% confidence interval {CI}: 0.60–0.82]; specificity
0.96 [0.94–0.98]; eight studies) may result in 216 (180–246) true positives, 28 (14–42)
false positives, 672 (658–686) true negatives, and 84 (54–120) false negatives per
1000 men. Systematic biopsy (sensitivity 0.63 [0.19–0.93]; specificity 1.00 [0.91–1.00];$ This article is based on a Cochrane Review published. Drost FH, Osses DF, Nieboer D, Steyerberg
EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic
biopsy for detecting prostate cancer. The Cochrane Database of Systematic Reviews 2019;4:
Cd012663. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/full.
Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback,
and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of
the review.
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four studies) may result in 189 (57–279) true positives, 0 (0–63) false positives,
700 (637–700) true negatives, and 111 (21–243) false negatives per 1000 men.
Agreement analyses: With a direct comparison of the MRI pathway with systematic
biopsy concerning significant disease, we found pooled detection ratios of 1.05
(95% CI: 0.95–1.16; 20 studies) in biopsy-naive men and 1.44 (1.19–1.75; 10 studies)
in men with a prior-negative biopsy. Concerning insignificant disease, we
found detection ratios of 0.63 (95% CI: 0.54–0.74), and 0.62 (95% CI: 0.44–0.88),
respectively.
Conclusions: MRI pathway had the most favourable outcome in significant and
insignificant prostate cancer detection compared with systematic biopsy. The cer-
tainty in our findings was reduced by study limitations.
Patient summary: We reviewed recent advances in prostate biopsy by magnetic
resonance imaging (MRI) guidance and targeting for prostate cancer detection in
comparison with standard diagnosis by systematic biopsies. The findings of this
Cochrane review suggest that MRI pathway is better than systematic biopsies in
making a correct diagnosis of clinically important prostate cancer and reducing
redundant biopsies and the detection of unimportant cancers substantially. However,
MRI pathway still misses some men with important prostate cancer. Therefore,
further research in this area is important.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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To reduce overdiagnosis and overtreatment of indolent
prostate cancer, while improving the detection of clinically
significant prostate cancer and reducing the number of
biopsy procedures, we need more accurate diagnostic
methods and better risk stratification [1]. In a recent
international multicentre randomised controlled trial,
magnetic resonance imaging (MRI) in combination with
MRI-targeted biopsy (MRI pathway) detected an absolute
12% more clinically significant prostate cancer and 13% less
indolent prostate cancer than systematic biopsy in biopsy-
naive men, and achieved 28% reduction of biopsies, because
men with negative MRI did not receive prostate biopsy
[2]. These results indicate that prebiopsy MRI and MRI-
targeted biopsy in the presence of an MRI-suspicious lesion
would be superior to a systematic biopsy. If this is
confirmed by other studies and longer follow-up of men
who were not biopsied, it may initiate a change to
guidelines.
Previous systematic reviews on diagnostic performances
of the MRI pathway or prebiopsy MRI approach [3–11] have
been based on study designs that did not accurately capture
target conditions and index or reference test definitions,
leading to a number of biases and inaccurate findings.
Studies in these reviews included mainly men with positive
MRI and disregarded men with negative MRI, inevitably
leading to inaccurate true- and false-negative values of the
MRI pathway. In addition, these reviews used systematic
biopsy or radical whole-mount surgical specimens as
reference standards, which inherently have a number of
biases. Furthermore, the established definitions of clinically
significant prostate cancer, based on histology from
systematic biopsy and possibly additional nonhistological
parameters, cannot be applied to results from the MRI
pathway [12]. In this (copublished) Cochrane review and
meta-analysis [13] we have largely overcome these limita-
tions.Please cite this article in press as: Drost F-JH, et al. Prostate Magn
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.0232. Evidence acquisition
For further detailed information on methods, we refer to the
original Cochrane review [13].
2.1. Objectives
We aimed to determine the diagnostic accuracy of the index
tests MRI only, MRI-targeted biopsy, MRI pathway (MRI
with or without MRI-targeted biopsy), and systematic
biopsy, as compared with template-guided biopsy as the
reference standard, in detecting International Society of
Urological Pathology (ISUP) grade 2 or higher (primary
target condition), grade 3 or higher, and grade 1 prostate
cancer (secondary target condition). Furthermore, we
aimed to determine the agreement and disagreement,
and the potential change in the number of biopsy
procedures between the two index tests, MRI pathway,
and systematic biopsy, for detecting the primary and
secondary target conditions.
2.2. Inclusion criteria
2.2.1. Types of studies
We considered any cross-sectional study, if it investigated
(Fig. 1) the following: (1) diagnostic test accuracy of one or
more of the index tests (MRI, MRI pathway;including MRI-
targeted biopsy], or systematic biopsy) verified by the
reference standard (template-guided biopsy), with each
index test and reference standard performed in the same
men or compared as in a randomised trial of test accuracy;
or (2) agreement evidence between the MRI pathway and
systematic biopsy, with each test performed in the same
men.
Studies involving MRI had to report on both MRI-
positive and MRI-negative men. The primary target
condition had to be reported on a per-participant basis
for all studies (Fig. 2).etic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
Fig. 1 – Clinical pathway flow diagram and study design.
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The study population consisted of men with a clinical
suspicion of prostate cancer (based on prostate-specific
antigen or digital rectal examination outcome) in the
biopsy-naive or prior-negative biopsy setting (or a mix of
both).
2.2.3. Index tests
MRI (index test 1) comprised at least T2-weighted imaging
and one functional imaging technique (diffusion-weighted
imaging or dynamic contrast-enhanced imaging), reported
according to any MRI-scoring system, mainly based on a
five-point scale (Likert or Prostate Imaging Reporting and
Data System) [14,15]. We defined the default threshold for
MRI-positivity as 3/5 or more where possible. MRI-targeted
biopsy (index test 2) included only MRI-positive men. The
MRI pathway (index test 3) included MRI-positive men (in
whom MRI-targeted biopsy was performed) and MRI-
negative men (in whom no MRI-targeted biopsy was
performed). Systematic biopsy (index test 4) included
either systematic transrectal or transperineal ultrasound-
guided biopsies. We defined the MRI pathway and
systematic biopsy as positive when histopathology of one
of the target conditions in the biopsy cores was confirmed.
2.2.4. Reference standard
Template-guided biopsy, including transperineal template-
guided mapping biopsy and the template-guided saturation
biopsy, served as the reference standard [16,17]. We defined aPlease cite this article in press as: Drost F-JH, et al. Prostate Magne
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.023positive template-guided biopsy as histopathological confir-
mation of one of the target conditions within the biopsy cores.
2.2.5. Target conditions
We solely focused on target conditions based on histological
definitions according to the ISUP grading, as was recom-
mended by International Working Group on Standards of
Reporting for MRI-targeted biopsy studies (START) in order
to overcome differences between definitions and biopsy
methods [18]. The primary target condition was clinically
significant prostate cancer, defined as ISUP grade 2 or higher
based on histopathology findings, and scored as Gleason
score (GS) 3 + 4 or higher [19]. Secondary target conditions
were grade 1 (GS 3 + 3, indolent prostate cancer) and grade
3 or higher (GS 4 + 3 or higher).
2.3. Search strategy
We performed a comprehensive search with no restriction
on language or status of publication (including on-going
studies), in electronic databases (CENTRAL, MEDLINE,
Embase, and nine other databases), and updated to 31 July
2018 (Supplementary material, Appendix 1).
2.4. Data collection and analysis
2.4.1. Selection of studies, data extraction, and management
Two reviewers independently screened all abstracts and
full-text articles for eligibility, and extracted data using atic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
Fig. 2 – Study flowchart. csPCa = clinically significant prostate cancer; MRI = magnetic resonance imaging; MRI pathway = magnetic resonance imaging
with subsequent magnetic resonance imaging-targeted biopsy; PCa = prostate cancer.
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two tables for cross-classification of the index tests versus
reference standard for test accuracy data and the MRI
pathway versus systematic biopsy for agreement data,
based on per-participant data (Supplementary material,
Appendix 2).
2.4.2. Assessment of methodological quality
Two reviewers independently assessed all included studies
for methodological quality using the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool [20], tailored
to this Cochrane review [13].
2.4.3. Statistical analysis and data synthesis
For the test accuracy analysis, we calculated pooled
estimates of sensitivity and specificity using the bivariate
model [21]. For the agreement analysis (MRI pathway vs
systematic biopsy), we calculated the proportion of
detected cases (total number of cancers) as the number
of concordant positive results plus the number of discordant
positive results of both tests (Supplementary material,
Appendix 2). We calculated the detection rate of either test
as the number of positive results of that test divided by the
total number of cancers detected. We synthesised pooled
estimates of detection ratios (detection rate of MRI
pathway/detection rate of systematic biopsy) by performingPlease cite this article in press as: Drost F-JH, et al. Prostate Magn
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.023random-effect meta-analyses. We used mixed models
(multinomial logistic regression models with a random
intercept for study effects) to calculate pooled proportions
of concordance and discordance between tests (Cochrane
review [13]). Added value (discordance) data were con-
structed such that we assessed the tests as add-on tests (ie,
considering reclassification by each test; Supplementary
material, Appendix 3). We used Statistical Analysis Software
(SAS), version 9.3, for Windows and R version 3.5.0 to
perform all statistical analyses.
2.4.4. Investigations of heterogeneity and sensitivity analyses
To explore sources of heterogeneity, we assessed covari-
ates by adding them one by one in our bivariate model:
population setting, MRI magnet strength, MRI sequences,
MRI-positivity threshold, endorectal coil, MRI-targeted
biopsy method, biopsy approach, and radiologists’ experi-
ence. We tested the same covariates using meta-regression
techniques for the detection ratio in the agreement
analysis.
2.4.5. Certainty of evidence
We rated the certainty of evidence on a per-outcome
basis according to Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) guidance for
studies of diagnostic accuracy [22]. For the four mainetic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
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GRADEpro GDT.
3. Evidence synthesis
For further detailed information on results, we refer to the
original Cochrane review [13].
3.1. Results of the search
A total of 43 studies were eligible for inclusion in this review
(Fig. 1) and provided data for multiple tests (Supplementary
material, Appendix 4). Eighteen studies addressed the test
accuracy analysis (index tests vs reference standard):
15 studies on MRI, eight studies on MRI, MRI-targeted
biopsy, and MRI pathway in the same men and four studies
on systematic biopsy (Table 1). These studies included
6871 men, of whom 5075 were biopsy naive, and 1796 had a
history of at least one prior-negative biopsy. Twenty-five
studies addressed the agreement analysis between MRI
pathway and systematic biopsy in detecting prostate cancer
with 6944 men, of whom 5353 were biopsy naive and
1591 had a history of at least one prior-negative biopsy
(Table 1).
3.2. Methodological quality of included studies
As a result of QUADAS-2 assessment (Supplementary Fig. 2),
we acknowledge overall concerns about the independence
and applicability of tests in both test accuracy and
agreement analyses, for which we performed sensitivity
analyses to exclude studies with such quality concerns.
3.3. Findings
3.3.1. Test accuracy analysis (index tests verified by reference
standard)
3.3.1.1. Detection of grade 2 or higher prostate cancer. MRI (pooled
sensitivity of 0.91 [95% confidence interval {CI} 0.83–0.95],
specificity of 0.37 [0.29–0.46]; 12 studies, 3091 men; Table 2)
at a baseline prevalence of 30% (300/1000) may result in 273
(249–285) true positives, 441 (378–497) false positives, 259
(203–322) true negatives, and 27 (15–51) false negatives per
1000 men (Table 3). Hence, MRI did not identify 9% (27/300)
of men with grade 2 or higher prostate cancer.
These accuracy and predictive metrics are also presented
for the index tests MRI-targeted biopsy, MRI pathway, and
systematic biopsy (Tables 2 and 3). MRI-targeted biopsy,
MRI pathway, and systematic biopsy missed, respectively,
20% (60/300), 28% (84/300), and 37% (111/300) of men with
grade 2 or higher prostate cancer at the prevalence of 30%
(300/1000), identified by the reference standard. Implica-
tions of these results, taking into account each step in the
MRI pathway (MRI with subsequent MRI-targeted biopsy in
MRI-positive men only) and systematic biopsy, are shown in
Fig. 3.
A comparison of MRI with MRI pathway showed a
substantial decrease in sensitivity (from 0.91 to 0.72; Fig. 4)
and an increase in specificity (from 0.37 to 0.96), whichPlease cite this article in press as: Drost F-JH, et al. Prostate Magne
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.023were both statistically significant (p < 0.01; Table 2).
Comparing MRI pathway with systematic biopsy showed
a substantial decrease in sensitivity (0.72 vs 0.63; p = 0.06;
Table 2) and similar specificities (Fig. 4).
At a baseline prevalence of 30% grade 2 or higher prostate
cancer, the negative predictive values for MRI, MRI-targeted
biopsy, MRI pathway, and systematic biopsy are 91% (86–
94%), 92 (88–94%), 89% (85–92%), and 86% (65–95%),
respectively (Table 2). Consequently, in the MRI pathway,
negative MRI falsely predicts the absence of grade 2 or
higher prostate cancer in 9% of men, while a negative
systematic biopsy falsely predicts the absence of grade 2 or
higher prostate cancer in 14% of men.
3.3.1.2. Detection of grade 1 prostate cancer. The pooled sensitivi-
ty and specificity for detecting grade 1 prostate cancer of
all index tests are shown in Table 2. Comparing the
sensitivity of the MRI pathway and systematic biopsy, the
MRI pathway potentially avoided the detection of 66% of
men with grade 1 prostate cancer, whereas systematic
biopsy potentially avoided 45% of men with grade
1 prostate cancer (p = 0.52).
3.3.1.3. Detection of grade 2 or higher prostate cancer at a higher MRI-
positive threshold. In clinical practice, lesions with an MRI
suspicion score of 3 (likelihood for clinically significant
cancer is equivocal [23]) might or might not be targeted
with biopsies. By increasing the threshold of MRI positivity
from 3/5 to 4/5, the proportion of negative MRI increased
from 30% (23–38%) to 59% (43–74%). The pooled sensitivity
of MRI for detecting grade 2 or higher prostate cancer
decreased from 0.89 (0.82–0.94) to 0.72 (0.52–0.86). The
pooled specificity increased from 0.39 (0.32–0.47) to 0.78
(0.68–0.86). Consequently, with a threshold 4/5 for MRI
positivity, negative MRI missed identifying 28% of men with
grade 2 or higher prostate cancer.
3.3.2. Agreement analysis between MRI pathway and systematic
biopsy
In this section, we focused on agreement and disagreement
(concordance and discordance) in the number of target
conditions identified by the MRI pathway and systematic
biopsy.
3.3.2.1. Detection of grade 2 or higher prostate cancer. In a mixed
population (of biopsy-naive and prior-negative biopsy
men), the pooled detection ratio of grade 2 or higher
prostate cancer was 1.12 (1.02–1.23; 25 studies, 6944 men),
meaning that the MRI pathway increased the detection rate
of grade 2 or higher prostate cancer by 12% compared with
systematic biopsy.
For men in the biopsy-naive setting, cancer proportion
(total prostate cancer detected by both tests) was 27.7%
(23.7–32.6%; 20 studies, 5219 men) versus prior-negative
biopsy setting of 22.8% (20.0–26.2%; 10 studies, 1564 men;
Table 4). The pooled detection ratios for grade 2 or higher
prostate cancer were 1.05 (0.95–1.16), and 1.44 (1.19–1.75),
respectively (p < 0.01; Fig. 5). When focusing on only MRI-
positive men in both subgroups, the pooled detection ratiotic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
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Lee (2016) MRI pathway
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1–4; 2 Cognitive Transrectal NA No G = 1, 1, 2,
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1–5; 3 In-bore Transrectal NA Yes G = 1, 1, 2,
3
Prospective Yes Bx naive 626 65 (59–68d) 6.4 (4.6–
8.2d)
55 (41–77d)
Bx = biopsy; ISUP G = International Society of Urological Pathology grade; MRI = magnetic resonance imaging; MRI pathway = magnetic resonance imaging with or without magnetic resonance imaging-targeted biopsy;
MRI TBx = magnetic resonance imaging-targeted biopsy; N = number; NA = not applicable; NR = not reported; PSA = prostate-specific antigen; SBx = systematic biopsy; SD = standard deviation; TSB = transperineal
saturation biopsy; TTMB = transperineal template mapping biopsy.
a Included participants were part of the same study cohort (no randomised populations were included).
b Included participants were part of the same study cohort (no randomised populations were included).
c Transrectal.
d Interquartile range (as opposed to range).
e Ginsburg biopsies.
f Mean value (as opposed to median value).
g Transperineal optimised prostate biopsy.
h In-house transperineal saturation biopsy.
































































































































Table 2 – Diagnostic accuracy and predictive metrics of the index tests verified by template-guided biopsy as the reference standard for different target conditions














p value NPVd (95% CI) PPVd (95% CI)
ISUP G  2 prostate cancer MRI 3091 (12) 0.29 (0.22–0.37) 0.91 (0.83–0.95) 0.37 (0.29–0.46) p < 0.01e 0.29 (0.22–0.38) 0.30 0.91 (0.86–0.94) 0.38 (0.36–0.40)
MRI Tbxf 1553 (8) NA 0.80 (0.69–0.87) 0.94 (0.90–0.97) 0.34 (0.24–0.46) 0.92 (0.88–0.94) 0.85 (0.77–0.91)
MRI pathway 2257 (8) 0.29 (0.24–0.35) 0.72 (0.60–0.82) 0.96 (0.94–0.98) p = 0.06g 0.26 (0.18–0.36) 0.89 (0.85–0.92) 0.90 (0.83–0.94)
SBx 3421 (4) NA 0.63 (0.19–0.93) 1.00 (0.91–1.00) 0.34 (0.21–0.51) 0.86 (0.65–0.95) 1.00 (0.73–1.00)
ISUP G  3 prostate cancer MRI 1438 (7) 0.31 (0.21–0.42) 0.95 (0.87–0.99) 0.35 (0.26–0.46) IDe 0.14 (0.08–0.23) 0.15 0.98 (0.95–0.99) 0.21 (0.19–0.23)
MRI Tbxf 428 (3) NA ID ID 0.21 (0.12–0.35) ID ID
MRI pathway 604 (3) 0.29 (0.26–0.33) ID ID IDg 0.16 (0.09–0.27) ID ID
SBx 626 (2) NA ID ID ID ID ID
ISUP G = 1 prostate cancer MRI 1764 (10) 0.28 (0.20–0.38) 0.70 (0.59–0.80) 0.27 (0.19–0.37) p < 0.01e 0.20 (0.17–0.23) 0.20 0.79 (0.74–0.82) 0.20 (0.18–0.21)
MRI Tbxf 497 (5) NA 0.51 (0.21–0.81) 1.00 (0.77–1.00) 0.22 (0.19–0.26) 0.89 (0.80–0.94) 0.97 (0.21–1.00)
MRI pathway 681 (5) 0.24 (0.16–0.36) 0.34 (0.19–0.53) 1.00 (0.90–1.00) p = 0.52g 0.21 (0.18–0.24) 0.86 (0.82–0.89) 0.95 (0.37–1.00)
SBx 3421 (4) NA 0.55 (0.25–0.83) 0.99 (0.81–1.00) 0.20 (0.16–0.25) 0.90 (0.81–0.95) 0.94 (0.37–1.00)
CI = confidence interval; ISUP G = International Society of Urological Pathology grade; ID = inadequate data; MRI = magnetic resonance imaging; MRI pathway = magnetic resonance imaging with or without magnetic
resonance imaging-targeted biopsy; MRI TBx = magnetic resonance imaging-targeted biopsy; NA = not applicable; NPV = negative predictive value; PPV = positive predictive value; SBx = systematic biopsy.
a Data did not allow differentiation between the mix of included participants (biopsy-naive and prior-negative biopsy men).
b Prevalence is pooled estimate of all detected cancer by template-guided biopsy.
c Assumptive prevalence is an extrapolation from the pooled estimates of all detected cancer by template-guided biopsy per target condition. This assumptive prevalence is necessary for adequate comparison of PPVs and
NPVs between index tests.
d Based on the Bayes’ theorem using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio and the point estimate of the prevalence.
e Comparing sensitivity between MRI and the MRI pathway.
f MRI-positive men only, instead of MRI-positive + MRI-negative men, implicating a higher risk profile and increased prevalence of clinically significant prostate cancer.


































































































































Table 3 – Summary of Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance for diagnostic test accuracy
of individual index tests
Population: Men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy-naive men) or a repeat
biopsy (prior-negative biopsy men)
Setting: University hospitals and specialised care centres
Reference
test:
Template-guided biopsy, which comprehensively samples all zones of the prostate
Threshold: ISUP grade 2 prostate cancer
Index test: MRI MRI-targeted biopsy MRI pathway Systematic biopsy
Threshold: MRI score 3 out of 5 ISUP grade 2 prostate cancer ISUP grade 2 prostate cancer ISUP grade 2 prostate cancer
Population: 3091 (12) 1553 (8) 2257 (8) 3421 (4)
Pooled sensitivity: 0.91 (95% CI: 0.83–0.95) 0.80 (95% CI: 0.69–0.87) 0.72 (95% CI: 0.60–0.82) 0.63 (95% CI: 0.19–0.93)
Pooled specificity: 0.37 (95% CI: 0.29–0.46) 0.94 (95% CI: 0.90–0.97) 0.96 (95% CI: 0.94–0.98) 1.00 (95% CI: 0.91–1.00)
Results per 1000 men tested (95% CI): at a baseline prevalence of 30% ISUP grade 2 prostate cancer by the reference test
True positives: 273 (249–285) 240 (207–261) 216 (180–246) 189 (57–279)
False negatives: 27 (15–51) 60 (39–93) 84 (54–120) 111 (21–243)
True negatives: 259 (203–322) 658 (630–679) 672 (658–686) 700 (637–700)
False positives: 441 (378–497) 42 (21–70) 28 (14–42) 0 (0–63)
Certainty of evidence (tp/fn): ** Lowa,b ** Lowa,b ** Lowa,b *** Moderatea,b,c
Certainty of evidence (tn/fp): ** Lowa,b ** Lowa,b ** Lowa,b ** Lowa,b,c
CI = confidence interval; fn = false negative—test indicates that clinically significant prostate cancer is not present but patient actually has clinically significant
prostate cancer; fp = false positive—test indicates clinically significant prostate cancer but patient actually does not have clinically significant prostate cancer;
ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; tn = true negative—test indicates that clinically significant prostate
cancer is not present and patient actually does not have clinically significant prostate cancer; tp = true positive—indicates clinically significant prostate cancer
and patient actually has clinically significant prostate cancer.
a A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.
b Considerable, clinically relevant, heterogeneity was observed across pooled study results.
c Important imprecision was noted, which contributed to decision to downgrade for inconsistency.
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(1.22–1.82), respectively.
3.3.2.2. Detection ratios for grade 1 prostate cancer. For men in the
biopsy-naive and the prior-negative biopsy settings, cancer
proportions of grade 1 prostate cancer were 27.2% (23.9–
31.1%; 17 studies, 4079 men) and 23.0% (18.0–30.2%; eight
studies, 1202 men), respectively; the pooled detection ratio
was 0.63 (0.54–0.74) and 0.62 (0.44-0.88), respectively
(Table 4).
3.3.2.3. Added values (discordance) in detection of grade 2 or higher
prostate cancer. Per 100 biopsy-naive men, the MRI pathway
detected approximately 23 men with grade 2 or higher
prostate cancer (23.4% [19.4–28.2]; Table 4). In addition to
the MRI pathway, systematic biopsy detected four addi-
tional men (4.3% [2.6–6.9%]). The total number of detected
cases was 27 (27.7% [23.7–32.6%]). Conversely, systematic
biopsy detected 21 men (21.4% [17.2–26.5%]) and the MRI-
pathway detected six additional men (6.3% [4.8–8.2%]).
Further details on mixed population and prior-negative
biopsy men are shown in the Cochrane review [13].
3.3.2.4. Added values (discordance) in detection of grade 1 prostate
cancer. Per 100 biopsy-naive men, the MRI pathway
detected approximately 11 men with grade 1 prostate
cancer (11.2% [8.4–14.9%]; Table 4). In addition to the MRI
pathway, systematic biopsy detected 10 additional men
(9.8% [8.0–11.8%]). The total number of detected cases was
21 (20.9% [18.0–24.7%]). Conversely, systematic biopsy
detected 19 men (18.5% [15.6–22.2%]) and the MRI pathway
detected two additional men (2.4% [1.4–4.0%]).Please cite this article in press as: Drost F-JH, et al. Prostate Magn
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.0233.3.2.5. Added values (discordance) in detection of grade 2 or higher
prostate cancer in MRI-positive and MRI-negative men. Stratifying
men further into having positive or negative MRI aids in
interpreting the added value in each of these categories. The
pooled proportions of positive and negative MRI were
respectively 67.0% (58.7–74.4%) and 33.0% (25.6–41.3%) in
the biopsy-naive setting, and were equivalent in the prior-
negative biopsy setting (Table 4).
Per 100 biopsy-naive men with positive MRI, the MRI
pathway detected approximately 39 men with grade 2 or
higher prostate cancer (39.2% [33.3–45.7%]). In addition to
the MRI pathway, systematic biopsy detected five men (4.9%
[2.8–8.3%]). The total number of detected cases was 44
(44.2% [38.6–50.4%]). Conversely, systematic biopsy
detected 34 men (34.4% [28.3–41.3%]) and the MRI pathway
detected 10 additional men (9.8% [7.1–13.2%]).
Per 100 biopsy-naive men with negative MRI, systematic
biopsy detected eight additional men with grade 2 or higher
prostate cancer (8.1% [5.6–11.6%]) and 18 additional men
with grade 1 prostate cancer (18.4% [14.2–23.7%]).
3.4. Heterogeneity analyses and sensitivity analyses
For the test accuracy analyses (index tests vs reference
standard [template-guided biopsy]), we observed consid-
erable heterogeneity in all index tests (Cochrane review
[13]). For the agreement analyses (MRI pathway vs
systematic biopsy), the heterogeneity (total tau-
square = 0.03) is illustrated in Figure 5. We found a
statistically significant difference in the detection ratio of
the MRI pathway versus systematic biopsy between the
subgroups of population (prior-negative biopsy vs biopsyetic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
Fig. 3 – Test results and implications of a hypothetical cohort of 1000 men tested for prostate cancer using the (A) MRI pathway and (B) systematic
biopsy. fn = false negative—test indicates that clinically significant prostate cancer is not present but patient actually has clinically significant prostate
cancer; fp = false positive—test indicates clinically significant prostate cancer but patient actually does not have clinically significant prostate cancer;
MRI = magnetic resonance imaging; tn = true negative—test indicates that clinically significant prostate cancer is not present and patient actually does
not have clinically significant prostate cancer; tp = true positive—indicates clinically significant prostate cancer and patient actually has clinically
significant prostate cancer. a The numbers in this figure are based on findings of the MRI pathway; therefore, MRI and MRI-targeted biopsy results
differ slightly from the numbers in Table 3. b Diagnoses by the MRI pathway and reference standard are based on biopsy histopathology, with equal
chance of up- or downgrading following radical prostatectomy.
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ity (Cochrane review [13]).
We performed sensitivity analyses for the detection of
grade 2 or higher prostate cancer by excluding studies
based on certain quality and additional criteria. Excluding
studies with a high or an unclear risk of bias or
applicability concern in one of the four QUADAS-2 domains
did not substantially change the accuracy results of MRI,
MRI-targeted biopsy, and the MRI pathway (Cochrane
review [13]).Please cite this article in press as: Drost F-JH, et al. Prostate Magne
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.0233.5. Discussion
This copublished Cochrane review presents the test
accuracy of prostate MRI, MRI-targeted biopsy, MRI
pathway (MRI with or without MRI-targeted biopsy), and
current standard testing with systematic biopsies in
prostate cancer diagnosis, using template-guided biopsy
sampling of the whole prostate as the reference standard.
This analysis provides evidence to determine their discrim-
inative value in current clinical practice. Both the MRItic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
Fig. 4 – Comparison of diagnostic test accuracy between MRI, MRI pathway, and systematic biopsy for detecting ISUP grade 2 and higher prostate
cancer. Summary ROC plots of MRI, MRI pathway, and systematic biopsy, verified by template-guided biopsy, with references to included studies (see
original review for further details [1]). A comparison of MRI with MRI pathway showed a substantial decrease in sensitivity (from 0.91 to 0.72) and an
increase in specificity (from 0.37 to 0.96), both of which were statistically significant (p < 0.01; Table 3). A comparison of the MRI pathway with
systematic biopsy showed a substantial decrease in sensitivity (from 0.72 to 0.63; p = 0.06; Table 3), and similar specificities. CI = confidence interval;
ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; ROC = receiver operating characteristics.
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EURURO-8458; No. of Pages 17pathway and the systematic biopsy missed considerable
proportions of grade 2 or higher prostate cancer, but the
MRI pathway missed less than the systematic biopsy.
Furthermore, the agreement analyses for detecting
prostate cancer between two index tests (the MRI pathway
and the current practice of systematic biopsy) provide
additional evidence for biopsy decision making, indicating
that the MRI pathway is more favourable than systematic
biopsy. The difference between the detection rates of the
MRI pathway and systematic biopsy was largest in men with
a prior-negative biopsy and insignificant in biopsy-naive
men. Evidence further suggested that the MRI pathway
beneficially missed more grade 1 prostate cancer than
systematic biopsy in both population types. Therefore, the
MRI pathway could potentially reduce the amount of
overdiagnosis, and harms related to surveillance and
overtreatment.
3.5.1. MRI-directed biopsy management
The benefits of using MRI (reducing biopsy procedures and
the overdiagnosis of grade 1 prostate cancer with improving
the detection of grade 2 and higher prostate cancer) arePlease cite this article in press as: Drost F-JH, et al. Prostate Magn
Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Pros
Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.06.023largest if MRI has a direct impact on biopsy decision
management and shared decision making. In other words,
the MRI before any biopsy and the MRI pathway as the
replacement for systematic biopsy, thus omitting system-
atic biopsy in specified circumstances, might provide the
most favourable diagnostic strategy.
Approximately one-third of all men had negative MRI.
This is a substantially large population in whom additional
systematic biopsies may potentially be avoided. Some
expert centres even report up to 50% MRI-negative men,
suggesting that an even larger population may benefit when
experience in MRI reading may improve [24]. The added
value of performing systematic biopsy in MRI-negative men
for the detection of grade 2 or higher prostate cancer could
be considered as limited with regard to total detection and
additional harms. As a prostate biopsy is associated with
patient burden, infection, morbidity, overdiagnosis, and
related overtreatment, it should be avoided when possible.
Omitting systematic biopsy in men with negative MRI might
be considered acceptable in some clinical situations.
However, benefits and harms are difficult to balance on
an individual basis. Therefore, men with negative MRI couldetic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.








































G = 1 4079 (17) NA 13.5 (10.7–17.2) 22.4
(19.1–26.3)
NA NA NA 0.630
(0.535–0.742)
0.000 0.905






















G = 1 2682 (16) NA 21.3 (17.0–26.9) 23.7 (19.6–29.1) NA NA NA 0.854
(0.743–0.982)
0.026 0.347






















G = 1 1287 (16) 18.4 (14.2–23.7) NA 18.4 (14.2–23.7) NA NA 18.4
(14.2–23.7)
NA NA NA
G  1 1343 (17) 25.5 (20.7–30.9) NA 25.5 (20.7–30.9) NA NA 25.5
(20.7–30.9)
NA NA NA
G  2 1343 (17) 8.1 (5.6–11.6) NA 8.1 (5.6–11.6) NA NA 8.1
(5.6–11.6)
NA NA NA
G  3 1297 (15) 3.0 (1.6–5.5) NA 3.0 (1.6–5.5) NA NA 3.0
(1.6–5.5)
NA NA NA
CI = confidence interval; ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; MRI pathway = magnetic resonance imaging with or without magnetic resonance imaging-targeted biopsy;
NA = not applicable; SBx = systematic biopsy.
a Proportion of participants with a positive or negative magnetic resonance imaging result, based on the studies reporting grade 2 or higher.
b Detection ratio is the detection rate of MRI pathway divided by the detection rate of systematic biopsy; the detection rate is the pooled number of positive results of the test divided by the pooled total number of positive
results from both tests.
c Evaluating the difference in detection ratios between the populations (biopsy-naive men vs prior-negative biopsy) for each target condition.



































































































































Fig. 5 – Forest plots of the agreement analysis (MRI pathway vs
systematic biopsy) for detecting grade 2 and higher prostate cancer.
The upper plot is based on all included men; the lower plot is based
on MRI-positive men. Continuous lines and brackets indicate study
individual 95% confidence intervals; diamonds indicate the pooled
summary estimate 95% confidence intervals; and dashed lines
indicate the pooled 95% prediction intervals. Detection rate = pooled
number of positive results of one test divided by the pooled total
number of positive results from both tests; detection
ratio = detection rate of the MRI pathway divided by detection rate of
SBx; MRI magnetic resonance imaging; MRI pathway: MRI with
subsequent MRI-targeted biopsy; RE model = random-effect model;
SBx = systematic biopsy; t2: tau-square (heterogeneity); + = positive
result;  = negative result.
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ing as a reasonable alternative for systematic biopsy, as also
argued by others [25–27].
Men with positive MRI have a clear indication for MRI-
targeted biopsy and can opt for additional systematic
biopsy. The added value of performing systematic biopsy in
MRI-positive men for the detection of grade 2 or higher
prostate cancer, however, could be considered as limited
with regard to total detection and additional harms. The
conditions under which systematic biopsy could be safely
avoided in men with positive MRI remain to be defined
[26,28,29]. When in this population, the MRI pathway does
not detect significant prostate cancer, a monitoring
approach could be introduced (instead of systematic
biopsy), based on clinical, biochemical, and imaging
parameters, and would result in a “safety net”. This safety
net could easily be adopted in the shared decision making in
current diagnostic work-up, as already recommended in
international guidelines [30–32].
3.5.2. Strength and weaknesses
For the in-depth analysis of quantity and quality of
evidence, strengths and weaknesses of included studies,
and strengths and weaknesses of the review process, we
refer to the original Cochrane review [13].
3.5.3. Context of other research
Distinguishing between biopsy-naive men and men with a
prior-negative biopsy is paramount in daily practice. The
agreement analysis, balancing the results of detecting grade
2 or higher prostate cancer, grade 1 prostate cancer, and
reduction of biopsies in MRI-negative men, can be
compared with selected high-quality studies (Supplemen-
tary Table 1). Recently, two multicentre randomised
controlled trials in biopsy-naive men [2,33] investigated
the MRI pathway and systematic biopsy. Furthermore, two
large high-quality prospective multicentre cohort studies
[24,34] investigated the agreement of prostate cancer
detection between the MRI pathway and systematic biopsy.
The most remarkable differences are the following. Both
randomised controlled trials showed that the MRI pathway
detected significantly more grade 2 or higher prostate
cancer than systematic biopsy [2,33], in contrast to the
results from the agreement analyses in this review [13],
including the two cohort studies [24,34]. Hence, while the
randomised controlled trials showed superiority of the MRI
pathway over systematic biopsy, the agreement studies did
not. Despite these inconsistencies, none of the studies
showed the MRI pathway to be inferior to systematic biopsy
in detecting grade 2 or higher prostate cancer. In addition, in
this Cochrane review, the proportion of men with grade 2 or
higher prostate cancer detected by the MRI pathway was
23.4% (95% CI: 19.3–28.1%), while this was substantially
higher in the two randomised controlled trials (Supple-
mentary Table 1). Regarding the proportions of men with
grade 1 prostate cancer, the MRI pathway in this reviewetic Resonance Imaging, with or Without Magnetic Resonance
tate Cancer: A Cochrane Systematic Review and Meta-analysis.
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two randomised controlled trials. Explanatory reasons
might be multiple and are discussed within the context
of this review (Cochrane review [13]).
3.5.4. Future research and perspectives
Quality control in the MRI pathway should be further
employed to improve MRI acquisition, MRI reading, and
MRI-targeted biopsy methods. The role of biparametric MRI
as well as the different approaches for targeted biopsy
(fusion, cognitive/visual, in bore), the route (transrectal/
transperineal), and the clinical validity and utility of
artificial intelligence with machine learning tools should
be further investigated. Education, training, procedural
standardisation, better imaging, and biopsy equipment
require a multidisciplinary approach in the management of
men with suspected prostate cancer [7,15,35,36]. This
diagnostic chain is only as strong as its weakest link
[37]. To improve the clinical utility of MRI-driven tests,
factors influencing the outcome of the MRI pathway (such
as per-lesion instead of a per-patient analysis, number of
MRI-targeted biopsy cores, MRI positivity threshold in
relation to clinical risk profiles, underlying MRI reading
problems, and inaccurate MRI-targeted biopsy) should be
further investigated. Risk calculators may aid in balancing
harms and benefits by further refining the selection of those
men who are at a risk of potentially life-threatening disease.
Research should be initiated with recently introduced
multivariable risk prediction models, including the MRI
suspicion score as an extra input variable, to better identify
those who would benefit from MRI and subsequent MRI-
targeted biopsy, or an additional systematic biopsy, or both
[38–42].
4. Conclusions
Balancing the potential benefits (reduction of biopsies and a
decrease of grade 1 prostate cancer overdiagnosis) against
the potential disadvantages (missing some grade 2 or higher
prostate cancer), in disregard to further economic metrics
(availability and costs), we conclude that the MRI pathway
may represent a more favourable diagnostic test than
systematic biopsy in all men suspected to have clinically
significant prostate cancer. Therefore, performing prostate
MRI before any biopsy should be structurally incorporated
in the diagnostic work-up. Our certainty in our findings was
reduced by study limitations. Furthermore, the MRI
pathway relies on experience and skills in acquiring and
reading MRI images, on targeting biopsy, and on high-end
equipment of MRI and biopsy hardware and software,
which are not yet widely available. Based on these
considerations, further improvement of the prostate cancer
diagnostic pathways should be pursued.
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